NEW YORK, June 2, 2026, 06:06 ET
VivoSim Labs (NASDAQ: VIVS) slipped in early pre-market trade Tuesday, last quoted at $1.29, off around 0.8%. The drug-testing microcap is trading just above its 52-week low of $1.22, with a market cap near $3.36 million.
That small move stands out since biotech was weak before the bell. The SPDR S&P Biotech ETF was off 2.2% in the latest trading. The iShares Nasdaq Biotechnology ETF lost 1.6%. That drop adds pressure, especially on smaller stocks where trading is light.
Capital stands out as the main problem. VivoSim reported $4.3 million in cash and cash equivalents at Dec. 31 in its latest quarter, with an accumulated deficit of $350.2 million. Negative operating cash flow was about $8.6 million for the first nine months of the fiscal year. Management said it had “substantial doubt” about the company’s ability to keep going, using standard language that flags possible need for extra funds. SEC
U.S. stocks were still in pre-market. Nasdaq runs pre-market trading from 4:00 a.m. to 9:30 a.m. ET, then regular trading kicks off at 9:30 a.m. and closes at 4:00 p.m. ET. June 2 isn’t on the 2026 Nasdaq holiday list.
No new VivoSim release has appeared on the company’s GlobeNewswire feed since April 28. Investors are left looking at earlier catalysts—mostly VivoSim’s statement that its NAMkind intestinal model and VitroSense AI tool called drug-induced diarrhea with 96% accuracy in training. New approach methodologies, or NAMs, are non-animal testing tech like human-cell platforms and computer models.
VivoSim Executive Chairman Keith Murphy said the company’s models produce data “in line with what is seen in humans.” In the same April release, Chief Scientific Officer Amar Sethi described the intestinal model as “world class,” according to the company. GlobeNewswire
The San Diego-based company, which used to be Organovo Holdings, says it is now a pharmaceutical and biotech services firm. It focuses on testing drugs in 3D human liver and intestine tissue models. According to Investing.com, the company was incorporated in 2007 and is still based in San Diego.
The regulatory shift is one reason the stock keeps getting notice. In April 2025, the FDA said it would cut back on animal-testing rules for monoclonal antibodies and other drugs, opening the way for methods like AI-based toxicity checks, use of cell lines, and organoid tests. FDA Commissioner Martin A. Makary called the move a “paradigm shift.” U.S. Food and Drug Administration
Competition is strong. Reuters says bigger companies like Charles River Laboratories, Certara, and Recursion Pharmaceuticals are putting money into AI and NAMs. Market data shows Charles River is worth around $8.9 billion, Certara about $965 million, and Recursion roughly $2.0 billion. VivoSim is much smaller and still has to show it can turn its models into regular sales.
Financing is still a focus. In an April 3 filing, VivoSim reported it brought in around $2.5 million in net proceeds from the first tranche of a best-efforts offering. The placement agent found buyers but did not backstop the total amount. A potential second tranche, worth up to $1 million, depended on the stock closing at or above $1.43 ahead of that tranche’s date and hitting a 10-day daily trading volume average of $100,000 or more.
But the trade carries risk both ways. VivoSim could benefit if more customers move to non-animal testing, making its story stronger. But if adoption stays slow, or if there are more equity raises, warrant exercises, or new listing worries, shares could come under pressure. The company has cautioned that any future stock sales might push the price down, and says it still needs to meet Nasdaq’s listing rules.
For now, traders aren’t reacting to new headlines. VivoSim is still being priced on the usual question of whether it can turn the current regulatory boost into real money and cut its need for extra cash soon enough.
